Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05262582
Other study ID # jianglei4
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 10, 2022
Est. completion date January 1, 2025

Study information

Verified date May 2022
Source Shanghai Pulmonary Hospital, Shanghai, China
Contact lei jiang, doctor
Phone +8613917912348
Email jiangleiem@aliyun.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Recently, robotic-assisted thoracic surgery (RATS) has become into as an alternative approach to either, open surgery or video-assisted thoracoscopic surgery. The superiorities of RATS have been reported in series studies, such as intuitive movements, tremor filtration, more degrees of manipulative freedom, motion scaling, and high-definition stereoscopic vision. However, the currently reported robotic thymectomy used 3 ports. Theoretically, less incisions may bring faster postoperative recovery, lighter postoperative pain and higher postoperative quality of life. The investigators have successfully performed robotic thymectomy through 2 ports and even 1 port. However, the potential benefit of less ports robotic thymectomy has not been verified through well-designed cohort study, so this clinical trial has been designed.


Description:

The gold standard technique for thymectomy used to be transsternal approach. Advancements in modern technology bring many evolutions in minimally invasive surgery such as Video-assisted thoracic surgery (VATS) thymectomy gained popularity after 2000s. Recently, robotic-assisted thoracic surgery (RATS) has become into as an alternative approach to either, open surgery or video-assisted thoracoscopic surgery. The superiorities of RATS have been reported in series studies, such as intuitive movements, tremor filtration, more degrees of manipulative freedom, motion scaling, and high-definition stereoscopic vision. However, the currently reported robotic thymectomy used 3 ports. Theoretically, less incisions may bring faster postoperative recovery, lighter postoperative pain and higher postoperative quality of life. The investigators have successfully performed robotic thymectomy through 2 ports and even 1 port. However, the potential benefit of less ports robotic thymectomy has not been verified through well-designed cohort study, so this clinical trial has been designed.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date January 1, 2025
Est. primary completion date July 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Patients with Myasthenia Gravis and(or) thymoma need to perform thymectomy. 2. Agree to accept Robotic Assisted Thoracic Surgery and have signed informed consent. Exclusion Criteria: 1. Cardiopulmonary function cannot tolerate thoracoscopic surgery or exist other contraindication. 2. Thymic carcinoma. 3. Thoracic deformity.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Sigle port RATS
The incision is performed in the 5-6th intercostal space under the breast folds without violating the mammalian tissue. This port is used for the camera and both arms simultaneously.
Two ports RATS
The incision is performed in the 4th intercostal space along anterior axillary fossa, for the camera and left arm. The other incision is subxiphoid longitudinal incision about 4cm for the right arm.

Locations

Country Name City State
China Shanghai Pulmonary Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Pulmonary Hospital, Shanghai, China

Country where clinical trial is conducted

China, 

References & Publications (4)

Curcio C, Scaramuzzi R, Amore D. Robotic-assisted thoracoscopic surgery thymectomy. J Vis Surg. 2017 Nov 7;3:162. doi: 10.21037/jovs.2017.10.01. eCollection 2017. Review. — View Citation

Kaba E, Cosgun T, Ayalp K, Alomari MR, Toker A. Robotic thymectomy-a new approach for thymus. J Vis Surg. 2017 May 8;3:67. doi: 10.21037/jovs.2017.03.28. eCollection 2017. Review. — View Citation

Luzzi L, Corzani R, Ghisalberti M, Meniconi F, De Leonibus L, Molinaro F, Paladini P. Robotic surgery vs. open surgery for thymectomy, a retrospective case-match study. J Robot Surg. 2021 Jun;15(3):375-379. doi: 10.1007/s11701-020-01109-z. Epub 2020 Jul 6. — View Citation

Peng M, Wang X, Chen C, Tan S, Liu W, Yu F. Report on 153 sequential three-incision robotic-assisted pulmonary resections by a single surgeon: technical details and learning curve. J Thorac Dis. 2020 Mar;12(3):741-748. doi: 10.21037/jtd.2019.12.116. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Post operation pain Measured with Visual Analogue Score (VAS-score),the minimum value is 1, the maximum value is 10, higher scores mean a worse outcome. 1 month after surgery
Secondary Surgical bleeding Surgical bleeding measured with milliliter During operation
Secondary Operation duration Operation duration measured with minute During operation
Secondary Quality of life after surgery Measured with European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (EORTC QLQ-C30 questionnaire), the higher scores mean a better outcome. 6 months
Secondary Curative effect Disease free survival 5 years after surgery 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Terminated NCT00818090 - Paclitaxel and Cisplatin for Thymic Neoplasm Phase 2
Completed NCT00332969 - Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma Phase 2
Completed NCT00921739 - Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Phase 1
Recruiting NCT05255965 - IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
Withdrawn NCT02948855 - Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
Completed NCT00387868 - Preoperative Treatment of Patients With High Risk Thymoma Phase 2
Completed NCT01272817 - Nonmyeloablative Allogeneic Transplant N/A
Recruiting NCT03466827 - Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Phase 2
Completed NCT02220855 - A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Phase 2
Completed NCT03288662 - Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors N/A
Active, not recruiting NCT01242072 - Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Phase 1
Recruiting NCT06029621 - Robot-assisted vs VATS for Thymoma N/A
Active, not recruiting NCT03921671 - Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) Phase 2
Active, not recruiting NCT01621568 - Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Phase 2
Terminated NCT01100944 - A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Phase 1/Phase 2
Active, not recruiting NCT03968315 - An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma N/A
Recruiting NCT04162691 - Single Cell Sequencing Analysis of Thymoma
Recruiting NCT06086327 - Application of 68Ga-Pentixafor PET/CT for Thymoma Early Phase 1
Completed NCT01364727 - A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Phase 2